Diadema Partners LP Mereo Biopharma Group PLC Call Options Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
Call Options
2 transactions
Others Institutions Holding MREO
# of Institutions
98Shares Held
98.2MCall Options Held
2.28MPut Options Held
761K-
Janus Henderson Group PLC London, X017.7MShares$29.4 Million0.02% of portfolio
-
Rubric Capital Management LP New York, NY15.3MShares$25.4 Million0.96% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.44MShares$15.7 Million1.35% of portfolio
-
Mangrove Partners New York, NY8.64MShares$14.3 Million3.39% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.71MShares$11.1 Million0.42% of portfolio
About Mereo Biopharma Group plc
- Ticker MREO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 124,986,000
- Market Cap $207M
- Description
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the tr...